The use of capsule endoscopy of the colon allows visualization of the colonic mucosa in most patients, but its sensitivity for detecting colonic lesions is low as compared with the use of optical colonoscopy. (ClinicalTrials.gov number, NCT00604162.)

Objective To evaluate the effect of different treatment strategies on enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome.Design Multicentre retrospective case-control study.Setting 23 hospitals in northern Germany.Participants 298 adults with enterohaemorrhagic E coli induced haemolytic uraemic syndrome.Main outcome measures Dialysis, seizures, mechanical ventilation, abdominal surgery owing to perforation of the bowel or bowel necrosis, and death.Results 160 of the 298 patients (54%) temporarily required dialysis, with only three needing treatment long term. 37 patients (12%) had seizures, 54 (18%) required mechanical ventilation, and 12 (4%) died. No clear benefit was found from use of plasmapheresis or plasmapheresis with glucocorticoids. 67 of the patients were treated with eculizumab, a monoclonal antibody directed against the complement cascade. No short term benefit was detected that could be attributed to this treatment. 52 patients in one centre that used a strategy of aggressive treatment with combined antibiotics had fewer seizures (2% v 15%, P=0.03), fewer deaths (0% v 5%, p=0.029), required no abdominal surgery, and excreted E coli for a shorter duration.Conclusions Enterohaemorrhagic E coli induced haemolytic uraemic syndrome is a severe self limiting acute condition. Our findings question the benefit of eculizumab and of plasmapheresis with or without glucocorticoids. Patients with established haemolytic uraemic syndrome seemed to benefit from antibiotic treatment and this should be investigated in a controlled trial.

PillCam colon capsule endoscopy (CCE) is an innovative noninvasive, and painless ingestible capsule technique that allows exploration of the colon without the need for sedation and gas insufflation. Although it is already available in European and other countries, the clinical indications for CCE as well as the reporting and work-up of detected findings have not yet been standardized. The aim of this evidence-based and consensus-based guideline, commissioned by the European Society of Gastrointestinal Endoscopy (ESGE) is to furnish healthcare providers with a comprehensive framework for potential implementation of this technique in a clinical setting.

This Capsule Endoscopy Structured Terminology (CEST) is a copy− righted work, protected by United States and worldwide copy− right laws and treaties. Users of the CEST are hereby granted a free license to use, copy or distribute the CEST in connection with supporting a structured terminology for capsule endoscopy, subject to the following conditions: 1. This copyright and terms of use notice must be displayed on each and every copy of the CEST, on all manuals and other mate− rials used in connection with the CEST, including without limita− tion electronic media (i. e., disks, CD−ROMs, etc.), and in all text files loaded onto electronic media or the Internet. Such copyright and terms of use notice shall not be removed, obscured, modified or otherwise hidden. All references to the CEST, in whole or in part, shall properly cite the CEST as the source for such reference. Proper citation shall read "Capsule Endoscopy Structured Termi− nology (CEST), Endoscopy 2005; 37: 951 ± 959 (February 16, 2002 Given Imaging Ltd.)". 2. The CEST shall not be used, in whole or in part, to harm or de− grade the reputation of Given Imaging or any participant in the Given Capsule Standard Working Group (the "GCSWG"). 3. Neither Given Imaging nor any participant in the GCSWG shall be liable for any errors or omissions contained in the CEST, or for any use you or any third party may make of the CEST. Given Ima− ging reserves the right to make changes to the CEST without no− tice. The information contained in the CEST is provided on an "as is" basis without any warranties, express or implied, including but not limited to the results or effects obtained through use of information, or that it is fit for any use intended or can be used without infringing the copyright or other proprietary rights of any third party. All express and implied warranties, including those relating to title, non−infringement, merchantability or fit− ness for a particular purpose, are hereby expressly disclaimed and excluded with respect to any information provided hereun− der.

No abstract